Test for statin side effects launched

June 1, 2012, Oxford University
Some people stop taking statins because of fears over side effects. Credit: iStockphoto/Marcelo Wain

(Medical Xpress) -- A simple diagnostic test developed at Oxford University, and launched today by Massachusetts-based Boston Heart Diagnostics, will identify those at increased risk of rare but serious side effects from taking cholesterol-lowering statin drugs.

Isis Innovation, the University's technology commercialisation company, granted Boston Heart Diagnostics an exclusive US license to the test in 2011. The test is now available for license in non-US territories, including the UK.

Researchers at Oxford University's Clinical Trial Service Unit, led by Professor Rory Collins, identified the genetic biomarker SLCO1B1, which is an effective identifier of patients at increased risk of myopathy – the onset of muscle aches, pains and weakness associated with statin therapy. This condition can be extremely unpleasant and occasionally becomes very serious.

"Lowering cholesterol with statin therapy results in a substantial reduction in heart attacks, stroke and cardiovascular mortality and larger reductions in produce larger benefits," said Professor Collins. "In rare cases, myopathy occurs in association with statin therapy, especially when the statins are given at higher doses and with certain other medications. Knowledge of the SLCO1B1 marker may help to achieve the benefits of statin therapy more safely and effectively."

Boston Heart Diagnostics has now launched the Statin Induced Myopathy (SLCO1B1) Genotype test. The test classifies individuals into high risk or low risk genotypes based on the presence or absence of the SLCO1B1 .

"Of course there are any number of reasons that people ignore their healthcare provider's advice, but statin-induced myopathy can be extremely unpleasant and, for a small percentage, completely debilitating – leading many to forego taking the potentially life-saving drug," said Boston Heart Diagnostics President and CEO Susan Hertzberg.

"We are delighted to assist in bringing this important new test to the US market through an exclusive arrangement with Boston Diagnostics," said Tom Hockaday, Managing Director of Isis Innovation. "The test has the potential to allow physicians worldwide to assist patients to choose the best and safest treatment option for their particular case.'

Explore further: Statins prevent cancer in heart transplant recipients

Related Stories

Statins prevent cancer in heart transplant recipients

May 20, 2012
Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

Intensive-dose statin therapy associated with increased risk of diabetes

June 21, 2011
An analysis of data from previously published studies indicates that intensive-dose statin therapy is associated with an increased risk of new-onset diabetes compared with moderate-dose therapy, according to a study in the ...

Recommended for you

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Researchers devise decoy molecule to block pain where it starts

January 16, 2018
For anyone who has accidentally injured themselves, Dr. Zachary Campbell not only sympathizes, he's developing new ways to blunt pain.

Scientists unleash power of genetic data to identify disease risk

January 16, 2018
Massive banks of genetic information are being harnessed to shed new light on modifiable health risks that underlie common diseases.

Blood-vessel-on-a-chip provides insight into new anti-inflammatory drug candidate

January 15, 2018
One of the most important and fraught processes in the human body is inflammation. Inflammatory responses to injury or disease are crucial for recruiting the immune system to help the body heal, but inflammation can also ...

Molecule produced by fat cells reduces obesity and diabetes in mice

January 15, 2018
UC San Francisco researchers have discovered a new biological pathway in fat cells that could explain why some people with obesity are at high risk for metabolic diseases such as type 2 diabetes. The new findings—demonstrated ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

PeterD
not rated yet Jun 05, 2012
Only an idiot would take statins since there is no evidence that shows that these drugs help you live longer. they are a complete fraud!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.